Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up (BERVOLT study: bevacizumab for RVO long-term follow-up)

Letter to the Editor


Bevacizumab Macular Edema Ranibizumab Aflibercept Retinal Vein Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest, and have no financial disclosures to report. Both authors (D.C. and M.C.) were involved in the design and conduct of the study, the collection, management, analysis and interpretation of the data, and the preparation, review and approval of the manuscript.

Compliance with ethical standards


The authors have full control of the primary data and have agreed to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data upon request.

Conflict of interest

All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.


  1. 1.
    Kornhauser T, Schwartz R, Goldstein M, Neudorfer M, Lowenstein A, Barak A (2015) Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up. (BERVOLT study: Bevacizumab for RVO long-term follow-up). Graefes Arch Clin Exp Ophthalmol. doi: 10.1007/s00417-01-3130-z Google Scholar
  2. 2.
    Epstein DLJ, Algvere PV, von Wendt G, Seregard S, Kvanta A (2012) Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 119:1184–1189CrossRefPubMedGoogle Scholar
  3. 3.
    Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRefPubMedGoogle Scholar
  4. 4.
    Brown DM, Wykoff CC, Wong TP, Mariani AF, Croft DE, Schuetzle KL (2014) Ranibizumab in preproliferative (ischemic) central retinal vein occlusion. The rubeosis and-VEGF (RAVE) trial. Retina 34:1728–1735CrossRefPubMedGoogle Scholar
  5. 5.
    Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMedGoogle Scholar
  6. 6.
    Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A (2014) Lont-term outcomes in patients with retinal vein occlusion treated with ranibizumab. The RETAIN study. Ophthalmology 121:209–219CrossRefPubMedGoogle Scholar
  7. 7.
    Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. Two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420CrossRefPubMedGoogle Scholar
  8. 8.
    Ogura Y, Roider J, Korobelnik JF, Holz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion. 18-month results of the phase 3 GALILEO study. Am J Ophthalmol 158:1032–1038CrossRefPubMedGoogle Scholar
  9. 9.
    Călugăru M (1987) Les resultats d’une enquete sur la survenue du glaucome neovasculaire après occlusion de la veine centrale de la retine. J Fr Ophtalmol 10:479–483PubMedGoogle Scholar
  10. 10.
    Chan A, Duker JS, Ko T, Fujimoto JG, Schuman JS (2006) Normal macular thickness measurements in healthy eyes using status optical coherence tomography. Arch Ophthalmol 124:193–198CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-NapocaCluj-NapocaRomania

Personalised recommendations